{"database": "lobbying", "table": "lobbying_activities", "is_view": false, "human_description_en": "where filing_period = \"second_quarter\", filing_year = 2021 and issue_code = \"PHA\" sorted by filing_year descending", "rows": [[2632549, "c03c74ec-8196-46c1-a043-70cb0ec13da6", "Q2", "4C COMMUNICATIONS, INC.", 323717, "HEALTHCARE LEADERSHIP COUNCIL", 2021, "second_quarter", "PHA", "The Treat Act", "HOUSE OF REPRESENTATIVES,SENATE", null, null, 0, 0, "2021-07-02T11:57:23.323000-04:00"], [2632559, "3ce8fd8d-8939-41e6-a9d8-ee4aed14bb7f", "Q2", "PENN AVENUE PARTNERS", 400918672, "ALKERMES, INC.", 2021, "second_quarter", "PHA", "Regulatory and legislative issues impacting Alkermes.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2021-07-02T12:47:30.710000-04:00"], [2633071, "f8c293a9-3cec-4c86-babd-e55028a78712", "Q2", "STONINGTON GLOBAL", 401105189, "SORRENTO THERAPEUTICS, INC.", 2021, "second_quarter", "PHA", "Regulatory approvals and funding for pharmaceutical products and devices", "Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office", 130000, null, 0, 0, "2021-07-06T13:17:21.127000-04:00"], [2633848, "7c5ac628-ce96-4601-bd38-9fec094a62d0", "Q2", "PENN AVENUE PARTNERS", 400918672, "UNITEDHEALTH GROUP, INC.", 2021, "second_quarter", "PHA", "Pharmacy benefit related issues.", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office", 90000, null, 0, 0, "2021-07-07T17:47:08.467000-04:00"], [2633948, "c73ff5b5-3718-401f-b944-79b0cd238fdc", "Q2", "AMERICAN COLLEGE OF CLINICAL PHARMACY", 57258, "AMERICAN COLLEGE OF CLINICAL PHARMACY", 2021, "second_quarter", "PHA", "Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs.", "Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE", null, 144981, 0, 0, "2021-07-08T09:10:46.310000-04:00"], [2634068, "4fae6076-de3c-40f0-b42c-b762bb5ed069", "Q2", "WATKINS & EAGER PLLC", 401104403, "ZYNERBA PHARMACEUTICALS, INC.", 2021, "second_quarter", "PHA", "Providing services on behalf of Zynerba to the pharmaceutical industry", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", 45000, null, 0, 0, "2021-07-08T11:18:35.717000-04:00"], [2634673, "b53db0a4-0d71-4208-bbe9-14010b33015e", "Q2", "INDEPENDENT PHARMACY COOPERATIVE", 313098, "INDEPENDENT PHARMACY COOPERATIVE", 2021, "second_quarter", "PHA", "IPC supports S. 1909/H.R. 3554, the Pharmacy DIR Reform to Reduce Senior Drug Costs Act. Support regulations/laws that would eliminate pharmacy DIR. \nIPC supports Pharmacists as Providers under Medicare Part B. IPC supports Pharmacy and Medically Underserved Areas Enhancement Act, H.R. 2759/S. 1362 \nIPC supports Pharmacists as Immunizers\nIPC supports 340B Program and contract pharmacies\nIPC supports Federal Retail Pharmacy COVID-19 Vaccination Program expansion.", "Centers For Medicare and Medicaid Services (CMS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE,White House Office", null, 30000, 0, 0, "2021-07-09T13:41:25.140000-04:00"], [2634708, "1743993d-d55b-47d0-9173-e07325a21413", "Q2", "340B HEALTH", 316434, "340B HEALTH", 2021, "second_quarter", "PHA", "The 340B Drug Pricing Program; S.773 - A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes; H.R. 853: Closing Loopholes for Orphan Drugs Act; H.R.3203 - To enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes; H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act; H.R.19 - Lower Costs, More Cures Act of 2021;", "Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE", null, 272268, 0, 0, "2021-07-09T14:42:00.983000-04:00"], [2634854, "6e91c212-04f3-4999-a98a-3b55bf3d7fe7", "Q2", "BUCHANAN INGERSOLL & ROONEY PC", 55291, "GALEPHAR PHARMACEUTICAL RESEARCH INC.", 2021, "second_quarter", "PHA", "Strategy development and implementation of federal government relations initiatives relating to the Food and Drug Administrations Pre-Approval of Supplemental through New Drug Application (NDA).", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2021-07-10T07:10:54.357000-04:00"], [2634855, "af5951c7-ed6d-482f-a200-1c8fde5f9c6d", "Q2", "BUCHANAN INGERSOLL & ROONEY PC", 55291, "OHEMO LIFE SCIENCES INC.", 2021, "second_quarter", "PHA", "Strategy development and implementation of federal government relations initiatives relating to the Food and Drug Administrations Pre-Approval of Supplemental through New Drug Application (NDA).", "HOUSE OF REPRESENTATIVES,SENATE", 10000, null, 0, 0, "2021-07-10T07:13:55.763000-04:00"], [2634860, "b74668fc-880d-4f22-8ce7-cae67bc2124f", "Q2", "BUCHANAN INGERSOLL & ROONEY PC", 55291, "GENERIC ANIMAL DRUG ALLIANCE", 2021, "second_quarter", "PHA", "Strategy development and implementation of federal government relations initiatives relating to generic animal drug industry.", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2021-07-10T07:15:57.160000-04:00"], [2635050, "5dbab130-0fbd-4032-aa13-0517058bf97c", "Q2", "PANNONE LOPES DEVEREAUX & O'GARA LLC", 401105501, "AMGEN", 2021, "second_quarter", "PHA", "Prescription drug pricing.", null, 9000, null, 0, 0, "2021-07-12T09:09:55.760000-04:00"], [2635081, "cdc9d2c4-beb6-4535-8521-9f28b0a543b8", "Q2", "NATIONAL ASSOCIATION OF CHAIN DRUG STORES", 26672, "NATIONAL ASSOCIATION OF CHAIN DRUG STORES", 2021, "second_quarter", "PHA", "Interfaced with the White House, Operation Warp Speed; HHS Secretary and team, and CDC to drive COVID testing & vaccinations across the nation.\n\nH.R. 1002 Debarment Enforcement of Bad Actor Registrants Act\n\nH.R. 1899 Ensuring Compliance Against Drug Diversion Act", "Centers For Disease Control & Prevention (CDC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office", null, 260000, 0, 0, "2021-07-12T10:46:29.487000-04:00"], [2635115, "484293c9-494f-4a01-acd1-f34e63b2c482", "Q2", "BUCHANAN INGERSOLL & ROONEY PC", 55291, "AIM IMMUNOTECH INC.", 2021, "second_quarter", "PHA", "Strategy development and implementation of company's federal government relations initiatives relating to research and development of therapeutics. FY 2022 Appropriations for Defense Department, and National Institutes of Health (NIH)", "Defense, Dept of (DOD),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Navy, Dept of,SENATE", 40000, null, 0, 0, "2021-07-12T11:27:08.793000-04:00"], [2635144, "1321c831-c121-462f-824c-40955827b58c", "Q2", "LUPIN PHARMACEUTICALS INC", 401104766, "LUPIN PHARMACEUTICALS INC", 2021, "second_quarter", "PHA", "None", "HOUSE OF REPRESENTATIVES,SENATE,U.S. Trade Representative (USTR)", null, 202049, 0, 0, "2021-07-12T11:53:37.030000-04:00"], [2635302, "7ea4b772-4387-4eaf-970e-f026bea3358d", "Q2", "CRISPR THERAPEUTICS, INC.", 401105184, "CRISPR THERAPEUTICS, INC.", 2021, "second_quarter", "PHA", "Coverage & reimbursement for Cell and Gene Therapies", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE", null, 100000, 0, 0, "2021-07-12T13:52:29.563000-04:00"], [2635427, "3939410d-c15a-473e-9e2c-e0630bd619ed", "Q2", "POLSINELLI PC", 314911, "TEVA PHARMACEUTICALS USA, INC.", 2021, "second_quarter", "PHA", "Issues related to pricing, reimbursement, and manufacturing of pharmaceutical products\nReview of Administration telehealth policies", "HOUSE OF REPRESENTATIVES,SENATE", 80000, null, 0, 0, "2021-07-12T15:32:17.040000-04:00"], [2635857, "067f0c87-268a-4a1e-8845-3689399904d7", "Q2", "PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION", 401103605, "PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION", 2021, "second_quarter", "PHA", "COVID-19 vaccine & therapeutic production, and pandemic protection.\nPharmaceutical supply chain and domestic manufacturing", "HOUSE OF REPRESENTATIVES,SENATE", null, 50000, 0, 0, "2021-07-13T11:33:23.487000-04:00"], [2635913, "3d300760-1db8-4e02-8b4e-baf5b1473ab7", "Q2", "RED+BLUE STRATEGIES", 400693064, "PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA)", 2021, "second_quarter", "PHA", "PL 117-2 - The American Rescue Plan Act Implementation - Issues related to policies focused on increasing access to health care coverage, including access to prescription drugs, for Americans with both public and private insurance.\n\nIssues related to Trump-era rules and regulations regarding Medicare rebate policies and PBM transparency.", "Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE", 70000, null, 0, 0, "2021-07-13T12:25:58.407000-04:00"], [2635920, "f834780d-9852-4c10-a098-f9713189b91e", "Q2", "RED+BLUE STRATEGIES", 400693064, "PEW CHARITABLE TRUSTS", 2021, "second_quarter", "PHA", "PL 117-2 - The American Rescue Plan Act Implementation - Issues related to the increased substance use disorder crisis in America, the need for a more robust pipeline for antibiotics to protect the nation, a more coherent HIT system to ensure robust public data and other related public health issues. \n\nS. 963 - Mainstreaming Addiction Treatment Act (The MAT Act) - Supporting access to MAT to help avoid opioid-related deaths in the country. \n\nS. 963 - Mainstreaming Addiction Treatment Act (The MAT Act) - Supporting access to MAT to help avoid opioid-related deaths in the country. \n\nS. 2076 - The Pioneering Antimicrobial Subscriptions to End Surging Resistance Act ( PASTEUR Act) - Issues related to improving the antibiotic pipeline to address antimicrobial resistance.\n\nIssues related to ensuring clear information regarding the safety of supplements. \n\nIssues related to dealing with antimicrobial resistance among the US population.", "HOUSE OF REPRESENTATIVES,SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)", 60000, null, 0, 0, "2021-07-13T12:40:00.663000-04:00"], [2635958, "2e407914-87cb-4d4b-8eb3-378cdcc59dd9", "Q2", "CONSUMER HEALTHCARE PRODUCTS ASSOCIATION", 29403, "CONSUMER HEALTHCARE PRODUCTS ASSOCIATION", 2021, "second_quarter", "PHA", "OTC switch process -- no bill number\n\nCures 2.0 -- no bill number", "Commerce, Dept of (DOC),Food & Drug Administration (FDA),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of", null, 189000, 0, 0, "2021-07-13T13:11:09.680000-04:00"], [2636349, "b5a756ce-587a-4541-9981-7ebcf905a2ee", "Q2", "MARSHALL & POPP, LLC", 401105121, "GENENTECH, INC.", 2021, "second_quarter", "PHA", "Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act.\n\nIssues related to supply chains, 340B, and the COVID-19 pandemic.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2021-07-13T17:21:09.987000-04:00"], [2636400, "57d25686-cb63-43c5-8555-5b1afb85bed1", "Q2", "MARSHALL & POPP, LLC", 401105121, "PFIZER, INC.", 2021, "second_quarter", "PHA", "Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act.\n\nIssues related to vaccine development and distribution.\n\nIssues related to supply chains, 340B, and the COVID-19 pandemic.", "Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2021-07-13T17:31:16.673000-04:00"], [2636406, "3b5262a0-3de6-46fe-aa52-0bd5157a906f", "Q2", "MARSHALL & POPP, LLC", 401105121, "PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA", 2021, "second_quarter", "PHA", "Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act.\n\nIssues related to vaccine development and distribution.\n\nIssues related to supply chains, 340B, and the COVID-19 pandemic.", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2021-07-13T17:35:18.060000-04:00"], [2636409, "99e043e9-f666-4333-a4e0-32bbb1487b63", "Q2", "MARSHALL & POPP, LLC", 401105121, "SANOFI U.S. SERVICES, INC.", 2021, "second_quarter", "PHA", "Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act.\n\nIssues related to vaccine development and distribution.\n\nIssues related to supply chains, 340B, and the COVID-19 pandemic.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2021-07-13T17:37:18.737000-04:00"], [2636497, "43f75837-b11a-4a4a-8679-bd89269121fa", "Q2", "HANCE SCARBOROUGH", 17443, "PHRMA", 2021, "second_quarter", "PHA", "Patent reform regarding pharmaceutical research & products.", "SENATE", 30000, null, 0, 0, "2021-07-14T00:09:45.030000-04:00"], [2636752, "7bdb3a53-5a69-49a1-bc1f-44c808655aa3", "Q2", "WAXMAN STRATEGIES", 401103693, "340B HEALTH", 2021, "second_quarter", "PHA", "Issues affecting the 340B drug pricing program; Appropriations for 340B program.", "HOUSE OF REPRESENTATIVES,SENATE", 45000, null, 0, 0, "2021-07-14T11:44:52.397000-04:00"], [2636857, "d9a0b958-e99f-4e44-aba0-355e29136903", "Q2", "FARRAGUT PARTNERS LLP", 401103938, "COMMUNITY ONCOLOGY ALLIANCE", 2021, "second_quarter", "PHA", "Issues related to pharmacy benefit managers. HR 3258 TACT Act", "Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 80000, null, 0, 0, "2021-07-14T12:43:22.297000-04:00"], [2636948, "3af014f0-dd08-4145-b9d0-2367ba6b93f9", "Q2", "FARRAGUT PARTNERS LLP", 401103938, "ONEONCOLOGY INC.", 2021, "second_quarter", "PHA", "Issues related to pharmacy benefit managers.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2021-07-14T13:27:50.200000-04:00"], [2637414, "88a4b57c-d2f7-40d0-998f-7eb3c22b59ae", "Q2", "BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC", 401104621, "BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC", 2021, "second_quarter", "PHA", "HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE", null, 110000, 0, 0, "2021-07-14T20:17:17.333000-04:00"], [2637507, "3de8514a-e6ae-45ca-9632-9d3d4ae55519", "Q2", "ACG ADVOCACY", 2057, "BAYER CROPSCIENCE LP", 2021, "second_quarter", "PHA", "Medication disposal.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2021-07-15T08:50:47.670000-04:00"], [2637553, "31326ac8-1646-4210-8600-6f1064482272", "Q2", "RUBICON ADVISORS, LLC", 315091, "DYNAVAX TECHNOLOGIES", 2021, "second_quarter", "PHA", "Prescription Drug User Fee, Biomedical Advance Research and Development Authority (BARDA)", "HOUSE OF REPRESENTATIVES,SENATE", 75000, null, 0, 0, "2021-07-15T09:37:00.263000-04:00"], [2637554, "bf18b12e-53d5-423a-93ef-4e540d6c7ebf", "Q2", "RUBICON ADVISORS, LLC", 315091, "DR. REDDY'S LABORATORIES, LTD", 2021, "second_quarter", "PHA", "Prescription Drug User Fee (PDUFA) re authorization.Generic Drug User Fee Act (GDUFA) re authorization. Border Adjustment Tax(BAT)issues", "Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE", 60000, null, 0, 0, "2021-07-15T09:39:00.760000-04:00"], [2637556, "c6546c0c-f03f-44f8-b965-32c834c93015", "Q2", "RUBICON ADVISORS, LLC", 315091, "CONSCIOUS DISCIPLINE", 2021, "second_quarter", "PHA", "Medicare", "HOUSE OF REPRESENTATIVES,SENATE", 67500, null, 0, 0, "2021-07-15T09:40:01.693000-04:00"], [2637558, "0229e5e9-9861-4d18-9bb1-386225aef5e1", "Q2", "RUBICON ADVISORS, LLC", 315091, "LANNETT COMPANY, INC", 2021, "second_quarter", "PHA", "Medicare and Medicaid, Generic Prescription, COVID-19 Stimulus", "Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)", 50000, null, 0, 0, "2021-07-15T09:42:02.610000-04:00"], [2637559, "d76c0b24-4d4a-4009-867c-d6658c06a9ec", "Q2", "RUBICON ADVISORS, LLC", 315091, "AVET PHARMACEUTICALS", 2021, "second_quarter", "PHA", "GENERIC DRUG PRICING,HOUSE COMMITTEE ON OVERSIGHT,GOVERNMENT REFORM, FOOD AND DRUG ADMINISTRATION AND COVID-19 DRUG SHORTAGES", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES", 30000, null, 0, 0, "2021-07-15T09:44:03.077000-04:00"], [2637562, "a5d584dc-7af9-464c-8fea-9f644de4dce3", "Q2", "ACADEMY OF MANAGED CARE PHARMACY", 48793, "ACADEMY OF MANAGED CARE PHARMACY", 2021, "second_quarter", "PHA", "Cures 2.0 - This bill is in discussion draft form. Lobbying on issues in bill related to medication adherence, caregiver training, pre-approval information exchange, cell and gene therapies, digital therapeutics, and confirmatory studies for accelerated approval drugs.\n\nPre-approval information exchange - lobbying for the introduction of a bill to codify FDA guidance creating a safe harbor for the practice of pre-approval information exchange between drug manufacturers and health plans.\n\nS.1909/HR. 3554 - A bill relating to direct and indirect remuneration in Medicare Part D.\n\nS. 1362 - Pharmacy and Medically Underserved Areas Enhancement Act - to provide for coverage under the Medicare program of pharmacist services", "Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", null, 50000, 0, 0, "2021-07-15T09:45:04.193000-04:00"], [2637567, "dfe8876c-d138-4627-9231-0efe74a86b8e", "Q2", "RUBICON ADVISORS, LLC", 315091, "ASCENDIS PHARMA, INC.", 2021, "second_quarter", "PHA", "Food and Drug Administration, Orphan Drugs", "Food & Drug Administration (FDA)", 60000, null, 0, 0, "2021-07-15T09:52:06.123000-04:00"], [2637809, "54c331f9-1c41-4fc9-af25-db797c5482b9", "Q2", "BLUE CROSS AND BLUE SHIELD OF KANSAS, INC.", 323876, "BLUE CROSS AND BLUE SHIELD OF KANSAS INC", 2021, "second_quarter", "PHA", "COVID-19 Testing; COVID-19 Vaccine Strategy and Treatment; Vaccine Rollout; Rx reform; Prescription drugs; Prescription Drug Reform;\n\nH.R. 3 - Lower Drug Costs Now Act\nSponsor: Rep. Frank Pallone (D-NJ-06)\n\nH.R. 2831 - Prompt Approval of Safe Generic Drugs Act\nSponsor: Rep. Nanette Barragan (D-CA-44)", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE", null, 10000, 0, 0, "2021-07-15T12:20:28.920000-04:00"], [2637857, "1252405d-0ca0-4879-8bc2-caa1f91446f1", "Q2", "KNIGHT CAPITOL CONSULTANTS", 40036301, "EQUASHIELD, LLC", 2021, "second_quarter", "PHA", "Provisions affecting vial reuse being discussed in connection with drug pricing legislation (no specific bills)", "Centers For Disease Control & Prevention (CDC),HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2021-07-15T12:52:47.987000-04:00"], [2638156, "47849297-beac-4e64-86f8-73d02404b3ef", "Q2", "NATIONAL COMMUNITY PHARMACISTS ASSOCIATION", 27478, "NATIONAL COMMUNITY PHARMACISTS ASSOCIATION", 2021, "second_quarter", "PHA", "S. 298 / H.R. 1829, the Pharmacy Benefit Manager Accountability Study Act of 2021;\nH.R. 3655, the Vaccine Injury Compensation Modernization Act of 2021;\nH.R. 3656, the Vaccine Access Improvement Act of 2021;\nH.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021;\nCOVID vaccine distribution", "Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Small Business Administration (SBA),White House Office", null, 370000, 0, 0, "2021-07-15T14:21:25.210000-04:00"], [2638326, "3eb566f6-32ba-45b5-98bd-2653619b6878", "Q2", "RED+BLUE STRATEGIES", 400693064, "COHERUS BIOSCIENCES", 2021, "second_quarter", "PHA", "S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system. \n\nIssues and policies that incent companies to increase their US footprint and adopt Made in America business practices. \n\nPolicies to help grow the biosimilars marketplace in the United States. \n\nPolicies focused on improving cancer care through access to affordable treatments.", "HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE", 60000, null, 0, 0, "2021-07-15T15:04:59.790000-04:00"], [2638582, "ba62e432-e669-4d5b-8889-17c9ccc0982c", "Q2", "HANCE SCARBOROUGH", 17443, "BOEHRINGER INGELHEIM USA CORPORATION", 2021, "second_quarter", "PHA", "Provide ongoing animal health policy monitoring, assessment, and research support.  Telemedicine/telehealth legislation.", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2021-07-15T16:02:09.783000-04:00"], [2638713, "83ad9312-9648-4d1a-bc64-aecec4b42470", "Q2", "NELSON MULLINS RILEY & SCARBOROUGH", 285871, "HEMOPHILIA OF GEORGIA", 2021, "second_quarter", "PHA", "340B Drug Pricing Program, Medicare, biomedical research, ACA implementation and COVID-19 response and relief legislation", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2021-07-15T17:55:46.587000-04:00"], [2638986, "8f59bb4d-36cf-4daa-9fee-52c321e56a60", "Q2", "PUBLIC CITIZEN", 32362, "PUBLIC CITIZEN", 2021, "second_quarter", "PHA", "Covid-19 Vaccine Manufacturing and access and related funding, drug price negotiation, FAIR drug pricing Act, clinical trial cost transparency, HR 3 Lower drug prices now act, HR 2096-SACKLER Act, Affordable medications act, prescription drug price spike remedies, Medical Innovation act, National Biomedical research act, USTR access to medicines position, HR 3778/S 1976 (NOVID act), Aducanumab, S.1435-Affordable Prescriptions for Patients act,", "Consumer Product Safety Commission (CPSC),Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,Occupational Safety & Health Administration (OSHA),Securities & Exchange Commission (SEC),SENATE,Treasury, Dept of,White House Office", null, 150000, 0, 0, "2021-07-16T08:31:35.043000-04:00"], [2639167, "b5a06b17-fb87-43e7-a14a-507afd417824", "Q2", "BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC.", 6382, "BLUE CROSS AND BLUE SHIELD OF FLORIDA INC", 2021, "second_quarter", "PHA", "COVID-19 Testing; COVID-19 Vaccine Strategy and Treatment; Vaccine Rollout; Rx Reform; Prescription Drugs; Prescription Drug Reform\n\nHR 3 (117th Congress), Elijah E. Cummings Lower Drug Costs Now Act, by Rep. Frank Pallone (D-NJ).  Establishes a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees.\n\nHR 550 (117th Congress), Immunization Infrastructure Modernization Act of 2021, by Rep. Ann Kuster (D-NH).  Amends the Public Health Service Act with respect to immunization system data modernization and expansion.\n\nHR 951 (117th Congress), Maternal Vaccination Act, by Rep. Terri Sewell (D-AL).  Directs the Secretary of Health and Human Services to carry out a national campaign to increase awareness of the importance of maternal vaccinations for the health of pregnant and postpartum individuals and their children.\n\nHR 979 (117th Congress), Vaccine Fairness Act, by Rep. Angie Craig (D-MN).  Directs the Secretary of Health and Human Services to submit to Congress a weekly report on COVID-19 vaccine distribution.\n\nHR 1452 (117th Congress), by Rep. Dan Crenshaw (R-TX).  Directs the Secretary of Health and Human Services to publish the formula the Secretary uses to determine the allocation of COVID-19 vaccines.\n\nHR 1978 (117th Congress), Protecting Seniors Through Immunization Act of 2021, by Rep. Ann Kuster (D-NH).  Amends title XVIII of the Social Security Act to provide information regarding vaccines for seniors as part of the Medicare & You handbook and to ensure that the treatment of cost sharing for vaccines under Medicare Part D is consistent with the treatment of vaccines under Medicare Part B.\n\nHR 2347 (117th Congress), Strengthening the Vaccines for Children Program Act of 2021, by Rep. Kim Schrier (D- WA).  Amends title XIX of the Social Security Act to ensure adequate access to vaccines under the Medicaid program and the Vaccines for Children program.\n\nHR 2831 (117th Congress), Prompt Approval of Safe Generic Drugs Act, by Rep. Nanette Diaz Barragan (D-CA).  Amends the Federal Food, Drug, and Cosmetic Act to provide for the prompt approval of drugs when safety information is added to labeling.\n\nHR 3013 (117th Congress), COVID Vaccine Transportation Access Act, by Rep. Nanette Diaz Barragan (D-CA).  Authorizes the Secretary of Health and Human Services to award grants for removing transportation barriers to accessing vaccines for SARS-CoV-2, including booster vaccines, for individuals from low-income communities, minority communities, or other communities in which transportation poses a barrier to health care access.\n\nHR 3655 (117th Congress), Vaccine Injury Compensation Modernization Act of 2021, by Rep. Lloyd Doggett (D-TX).  Amends the Public Health Service Act to make updates to the Vaccine Injury Compensation Program.\n\nHR 3742 (117th Congress), Vaccine INFO Act, by Rep. Gus Bilirakis (R-FL).  Requires the Secretary of Health and Human Services to issue revised regulations to require the dissemination of information on ACIP recommended immunizations to staff of nursing facilities.\n\nHR 3743 (117th Congress), Supporting the Foundation for the National Institutes of Health and the Reagan-Udall Foundation for the Food and Drug Administration Act, by Rep. Richard Hudson (R-NC).  Increases funding for the Reagan-Udall Foundation for the Food and Drug Administration and for the Foundation for the National Institutes of Health.", "Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),SENATE,White House Office", null, 150000, 0, 0, "2021-07-16T10:11:25.923000-04:00"], [2639185, "6e199a11-d153-407e-b541-08b2a212cf35", "Q2", "GUIDEWELL MUTUAL HOLDING CORPORATION", 401103191, "GUIDEWELL MUTUAL HOLDING CORPORATION", 2021, "second_quarter", "PHA", "COVID-19 Testing; COVID-19 Vaccine Strategy and Treatment; Vaccine Rollout; Rx Reform; Prescription Drugs; Prescription Drug Reform\n\nHR 3 (117th Congress), Elijah E. Cummings Lower Drug Costs Now Act, by Rep. Frank Pallone (D-NJ).  Establishes a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees.\n\nHR 550 (117th Congress), Immunization Infrastructure Modernization Act of 2021, by Rep. Ann Kuster (D-NH).  Amends the Public Health Service Act with respect to immunization system data modernization and expansion.\n\nHR 951 (117th Congress), Maternal Vaccination Act, by Rep. Terri Sewell (D-AL).  Directs the Secretary of Health and Human Services to carry out a national campaign to increase awareness of the importance of maternal vaccinations for the health of pregnant and postpartum individuals and their children.\n\nHR 979 (117th Congress), Vaccine Fairness Act, by Rep. Angie Craig (D-MN).  Directs the Secretary of Health and Human Services to submit to Congress a weekly report on COVID-19 vaccine distribution.\n\nHR 1452 (117th Congress), by Rep. Dan Crenshaw (R-TX).  Directs the Secretary of Health and Human Services to publish the formula the Secretary uses to determine the allocation of COVID-19 vaccines.\n\nHR 1978 (117th Congress), Protecting Seniors Through Immunization Act of 2021, by Rep. Ann Kuster (D-NH).  Amends title XVIII of the Social Security Act to provide information regarding vaccines for seniors as part of the Medicare & You handbook and to ensure that the treatment of cost sharing for vaccines under Medicare Part D is consistent with the treatment of vaccines under Medicare Part B.\n\nHR 2347 (117th Congress), Strengthening the Vaccines for Children Program Act of 2021, by Rep. Kim Schrier (D- WA).  Amends title XIX of the Social Security Act to ensure adequate access to vaccines under the Medicaid program and the Vaccines for Children program.\n\nHR 2831 (117th Congress), Prompt Approval of Safe Generic Drugs Act, by Rep. Nanette Diaz Barragan (D-CA).  Amends the Federal Food, Drug, and Cosmetic Act to provide for the prompt approval of drugs when safety information is added to labeling.\n\nHR 3013 (117th Congress), COVID Vaccine Transportation Access Act, by Rep. Nanette Diaz Barragan (D-CA).  Authorizes the Secretary of Health and Human Services to award grants for removing transportation barriers to accessing vaccines for SARS-CoV-2, including booster vaccines, for individuals from low-income communities, minority communities, or other communities in which transportation poses a barrier to health care access.\n\nHR 3655 (117th Congress), Vaccine Injury Compensation Modernization Act of 2021, by Rep. Lloyd Doggett (D-TX).  Amends the Public Health Service Act to make updates to the Vaccine Injury Compensation Program.\n\nHR 3742 (117th Congress), Vaccine INFO Act, by Rep. Gus Bilirakis (R-FL).  Requires the Secretary of Health and Human Services to issue revised regulations to require the dissemination of information on ACIP recommended immunizations to staff of nursing facilities.\n\nHR 3743 (117th Congress), Supporting the Foundation for the National Institutes of Health and the Reagan-Udall Foundation for the Food and Drug Administration Act, by Rep. Richard Hudson (R-NC).  Increases funding for the Reagan-Udall Foundation for the Food and Drug Administration and for the Foundation for the National Institutes of Health.", "Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office", null, null, 0, 0, "2021-07-16T10:16:32.493000-04:00"], [2639361, "83c41352-7527-44a2-8df5-db93784ddf6b", "Q2", "BROWN & FORTUNATO, P.C.", 401104878, "PROMPTCARE COMPANIES, INC.", 2021, "second_quarter", "PHA", "Issues related to Medicare home infusion therapy benefit and other health care issues.  Issues related to the Medicare DMEPOS competitive bidding program and Medicare coverage and payment for non-invasive ventilators.", "Centers For Medicare and Medicaid Services (CMS)", 20000, null, 0, 0, "2021-07-16T10:52:10.090000-04:00"], [2639655, "171d882f-aebf-4027-a334-b5afdb3d3f46", "Q2", "KOUNTOUPES DENHAM CARR & REID, LLC", 320918, "GLENMARK PHARMACEUTICALS, INC., USA", 2021, "second_quarter", "PHA", "Issues related to the implementation of H.R. 1319, the American Rescue Plan.  Issues related to affordability, essential medicine manufacturing and supply chain, and pricing of pharmaceuticals.  General issues related to the generic drug industry.  Issues related to H.R. 2853, the BLOCKING Act of 2021.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2021-07-16T11:58:29.223000-04:00"], [2639771, "2b0327da-cd15-45e0-94a6-56e63de90593", "Q2", "AMERICAN VETERINARY MEDICAL ASSOCIATION", 3630, "AMERICAN VETERINARY MEDICAL ASSOCIATION", 2021, "second_quarter", "PHA", "Prescription Mandate Legislation Draft \nCompounding Guidance (GFI 256)\nH.R. 841 Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; S. 1698 Hemp Access and Consumer Safety Act (Mark)", "Agriculture, Dept of (USDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 220000, null, 0, 0, "2021-07-16T12:20:52.393000-04:00"], [2640168, "f61a6f6d-a6c0-49cf-b666-b5d3906b0436", "2A", "AARP", 1694, "AARP", 2021, "second_quarter", "PHA", "No bill number. Discussed prescription drugs and Medicare.\n\nNo bill number - FY 2022 Agriculture, Rural Development & FDA Appropriations.", "Administration for Children & Families (ACF),Agriculture, Dept of (USDA),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Consumer Financial Protection Bureau (CFPB),Corporation for Natl & Community Service,Defense, Dept of (DOD),Equal Employment Opportunity Commission (EEOC),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),Internal Revenue Service (IRS),Justice, Dept of (DOJ),Labor, Dept of (DOL),Natl Institutes of Health (NIH),Natl Transportation Safety Board (NTSB),Office of Management & Budget (OMB),Office of Personnel Management (OPM),Office of the Comptroller of the Currency (OCC),Pension Benefit Guaranty Corporation (PBGC),Securities & Exchange Commission (SEC),SENATE,Social Security Administration (SSA),Transportation, Dept of (DOT),Treasury, Dept of,Veterans Affairs, Dept of (VA),White House Office", null, 2720000, 0, 0, "2021-07-16T13:47:26.323000-04:00"], [2640191, "1d6e9316-2e8a-4790-a86a-d59b412ead57", "Q2", "HANCE SCARBOROUGH", 17443, "ALLIANCE FOR PHARMACY COMPOUNDING", 2021, "second_quarter", "PHA", "Issues related to the regulation of pharmacy compounding.\n\nIssues related to preserving patient access to compounded medications.\n\nFiscal Year 2022 Appropriations", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2021-07-16T13:48:27.723000-04:00"], [2640269, "a8e85ca9-e28e-4ebb-a931-a1fdaee05f64", "Q2", "FLYNN & ASSOCIATES, INC.", 15020, "PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION", 2021, "second_quarter", "PHA", "H.R. 3 -  Price controls for prescription drugs.\nImportation of drugs from other countries.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2021-07-16T14:06:47.567000-04:00"], [2640375, "ca2c3809-4156-41e0-93f2-e246f9b17b50", "Q2", "LINCOLN PARK GROUP L.L.C.", 401104374, "CANADIAN INTERNATIONAL PHARMACY ASSOCIATION", 2021, "second_quarter", "PHA", "Support for S. 920/H.R. 2181 - A bill to amend the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors, pharmacies, and individuals and S. 259/H.R. 832 - Safe and Affordable Drugs from Canada Act; issues related to personal drug importation.", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2021-07-16T14:36:12.057000-04:00"], [2640599, "4477ae4b-f7e3-4756-9021-7c8281533333", "Q2", "KOUNTOUPES DENHAM CARR & REID, LLC", 320918, "CONSUMER HEALTHCARE PRODUCTS ASSOCIATION", 2021, "second_quarter", "PHA", "General issues related to over the counter pharmaceuticals, pharmaceutical supply chain and country of origin labeling, including S.1260, United States Innovation and Competition Act of 2021.  Implementation of the Over the Counter Monograph provisions included in PL 116-136, Coronavirus Aid, Relief and Economic Security Act.  Issues related to supplements.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2021-07-16T15:21:20.090000-04:00"], [2640717, "7a55d00c-8a21-4524-8595-98cd4edd1465", "Q2", "UNITED FOOD & COMMERCIAL WORKERS INTERNATIONAL UNION", 39121, "UNITED FOOD & COMMERCIAL WORKERS INTERNATIONAL UNION", 2021, "second_quarter", "PHA", "Met with Senate staff regarding prescription drug reform.", "HOUSE OF REPRESENTATIVES,SENATE", null, 190000, 0, 0, "2021-07-16T15:44:46.520000-04:00"], [2640905, "5d894fd8-2b21-4fc2-b362-b9d5d38fb1f8", "Q2", "FORBES-TATE", 400976792, "CALIFORNIA LIFE SCIENCES ASSOCIATION", 2021, "second_quarter", "PHA", "Issues related to the life sciences industry; Issues related to drug pricing and international reference pricing.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2021-07-16T16:23:35.373000-04:00"], [2640977, "049dbb77-da45-4623-af23-5f21842fb989", "Q2", "BROYDRICK & ASSOCIATES", 7268, "EXELA PHARMA SCIENCES", 2021, "second_quarter", "PHA", "Drug shortages and FDA approval, USTR acceptance.", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", null, null, 0, 0, "2021-07-16T16:35:57.020000-04:00"], [2641048, "a0c67346-44bd-4fa8-b294-a5affa70fc4c", "Q2", "BROYDRICK & ASSOCIATES", 7268, "TONIX PHARMACEUTICALS", 2021, "second_quarter", "PHA", "Funding new drug for PTSD and COVID 19.", "Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2021-07-16T16:48:24.467000-04:00"], [2641049, "4065651e-1e35-4abb-9e2b-dc6677f61c50", "Q2", "SIMS STRATEGIES, LLC", 401104546, "AMAG PHARMACEUTICAL", 2021, "second_quarter", "PHA", "Pharmaceutical issues related to womens health product access.", "HOUSE OF REPRESENTATIVES,SENATE", 80000, null, 0, 0, "2021-07-16T16:48:24.930000-04:00"], [2641234, "776eae36-0434-4205-980b-9a3259a23910", "Q2", "FORBES-TATE", 400976792, "MERCK", 2021, "second_quarter", "PHA", "Issues related to prescription drug pricing, vaccines, animal health, and maternal health.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2021-07-16T17:22:15.677000-04:00"], [2641297, "b35eb576-d7b2-4224-a94e-3edd445c5fbc", "Q2", "FOLEY & LARDNER LLP", 15042, "BLINK HEALTH LTD (A BERMUDA LIMITED COMPANY)", 2021, "second_quarter", "PHA", "Market-based solutions to drug pricing and chain pharmacy barriers to generic pharmaceutical price reduction.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2021-07-16T17:41:31.253000-04:00"], [2641586, "401fd9e9-8164-4011-ab93-153f22cbe072", "Q2", "REPUBLIC CONSULTING, LLC", 401016871, "IQVIA", 2021, "second_quarter", "PHA", "Monitored Health Data Policy.", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2021-07-17T09:41:27.690000-04:00"], [2641670, "ea16dba0-542f-49bf-aaad-877acd74b862", "Q2", "FORBES-TATE", 400976792, "PHRMA", 2021, "second_quarter", "PHA", "Issues pertaining to prescription drug pricing.", "HOUSE OF REPRESENTATIVES,SENATE", 80000, null, 0, 0, "2021-07-17T10:41:06.520000-04:00"], [2642114, "29cbeb88-4060-4fed-aa45-772d4057c895", "Q2", "BROWNSTEIN HYATT FARBER SCHRECK, LLP", 7257, "AKTIV PHARMA GROUP", 2021, "second_quarter", "PHA", "Supply chain issues related to production of pharmaceuticals", "SENATE", 20000, null, 0, 0, "2021-07-17T14:37:04.297000-04:00"], [2642160, "6053acee-e313-40cb-8a70-f82c9e89efcb", "Q2", "THE KUTLER GROUP", 401103966, "PRIME THERAPEUTICS", 2021, "second_quarter", "PHA", "drug pricing issues", "HOUSE OF REPRESENTATIVES,SENATE", 24000, null, 0, 0, "2021-07-17T15:01:19.390000-04:00"], [2642223, "c6676808-7b2e-41b1-8138-f8f18a874722", "Q2", "CAPITOL COUNSEL LLC", 313715, "EMD SERONO, INC.", 2021, "second_quarter", "PHA", "Monitoring and engaging on health policy proposals coming before the House of Representatives and the Administration pertaining to the availability and pricing of prescription drugs.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2021-07-17T15:21:38.317000-04:00"], [2642394, "3f6ee994-509c-4069-8db8-c2fe86ffa001", "Q2", "FORBES-TATE", 400976792, "INDEPENDENT PHARMACY COOPERATIVE", 2021, "second_quarter", "PHA", "Issues related to pharmacy regulation, the MAC Transparency Act, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2021-07-17T16:35:30.723000-04:00"], [2642628, "445214e9-2d51-42b8-b5c0-c239a80ce9e7", "2A", "KNIGHT CAPITOL CONSULTANTS", 40036301, "REGENXBIO", 2021, "second_quarter", "PHA", "Possible legislation which may affect Food and Drug Administration review of biologic products (no specific bill)", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2021-07-17T21:44:39.107000-04:00"], [2642643, "3a55754e-9fb8-4c68-b20c-1b389ddd46d3", "Q2", "SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING", 35968, "SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING", 2021, "second_quarter", "PHA", "Compounding, preparation, packaging and dispensing of radiopharmaceuticals", "Centers For Medicare and Medicaid Services (CMS),Energy, Dept of,Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Nuclear Regulatory Commission (NRC),Office of Science & Technology Policy (OSTP),SENATE", null, 52000, 0, 0, "2021-07-17T21:58:42.947000-04:00"], [2643277, "2063e0e5-7dc1-46b0-b6cf-ee2b75f6d915", "Q2", "FORBES-TATE", 400976792, "VERDE TECHNOLOGIES", 2021, "second_quarter", "PHA", "Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.", "HOUSE OF REPRESENTATIVES,SENATE", 80000, null, 0, 0, "2021-07-18T15:17:38.590000-04:00"], [2643413, "65710229-de48-4b49-bce3-a728f0026e2d", "Q2", "E3 STRATEGIC CONSULTING GROUP", 401104104, "HEINZ STRATEGIES LLC (ON BEHALF OF PILMA)", 2021, "second_quarter", "PHA", "Prescription drug industry issues relating to domestic construction and maintenance employment and all other issues affecting employment in the industry, generally;\nHR 3, Elijah E. Cummings Lower Drug Costs Now Act.", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2021-07-18T16:32:17.750000-04:00"], [2643414, "79b8b412-37a9-4907-a842-c35433b02a77", "Q2", "E3 STRATEGIC CONSULTING GROUP", 401104104, "PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION", 2021, "second_quarter", "PHA", "Prescription drug industry issues relating to domestic construction and maintenance employment and all other issues affecting employment in the industry, generally;\nHR 3, Elijah E. Cummings Lower Drug Costs Now Act", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2021-07-18T16:33:18.220000-04:00"], [2643497, "3c5518be-c173-4bbd-9e1e-b6975c6c3ef4", "Q2", "POLARIS GOVERNMENT RELATIONS, LLC", 307730, "CIGNA CORPORATION", 2021, "second_quarter", "PHA", "Issues related to drug pricing, generally", "HOUSE OF REPRESENTATIVES,SENATE", 90000, null, 0, 0, "2021-07-18T17:06:43.220000-04:00"], [2643778, "58933e38-8441-4745-a82d-55e841f13ab7", "Q2", "TARPLIN, DOWNS & YOUNG, LLC", 304736, "ASTRAZENECA", 2021, "second_quarter", "PHA", "Drug coverage & reimbursement\nvaccination\n\nno specific bills, Import Safety, drug development policy, drug shortages, supply chain integrity, Innovation, reimportation, transparency, 340B, pay for delay", "Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 80000, null, 0, 0, "2021-07-18T20:23:14.283000-04:00"], [2643808, "02866f7c-ebd8-4e5e-9808-db7f3eac131a", "Q2", "TARPLIN, DOWNS & YOUNG, LLC", 304736, "BIOTECHNOLOGY INDUSTRY ORGANIZATION", 2021, "second_quarter", "PHA", "H.R. 1319, American Rescue Plan of 2021\n\n\nno specific bills, Drug Safety, Prescription Drug Importation, Import Safety, supply chain integrity, biosimilars, patent settlements, break through therapies, Innovation, transparency\n\nno specific bills, Drug Safety, Prescription Drug Importation, Import Safety, supply chain integrity, biosimilars, PDUFA and associated policies, patent settlements, accelerated approval, break through therapies, compounding, user fee reauthorization, Innovation", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE", 80000, null, 0, 0, "2021-07-18T20:41:21.610000-04:00"], [2644042, "65579070-a332-4916-a928-7bf0706bfee8", "Q2", "VAN SCOYOC ASSOCIATES", 39837, "ZEBRA TECHNOLOGIES CORP.", 2021, "second_quarter", "PHA", "Temperature monitoring technology for COVID-19 vaccines, Domestic and International distribution related issues\n\nTemperature monitoring technology, generally", "SENATE", 30000, null, 0, 0, "2021-07-19T07:01:21.787000-04:00"], [2644339, "be8f4150-18e0-4fc7-b53c-f93607e4df24", "Q2", "ELI LILLY AND COMPANY", 13392, "ELI LILLY AND COMPANY", 2021, "second_quarter", "PHA", "Hospital discounts; 340B program", "Commerce, Dept of (DOC),Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)", null, 1675000, 0, 0, "2021-07-19T09:07:34.960000-04:00"], [2644561, "a9d4ecb7-391a-4001-9e26-7f0a5f35b60c", "Q2", "M.J. SIMON & COMPANY, LLC", 40026223, "NOBELPHARMA AMERICA", 2021, "second_quarter", "PHA", "FDA inspections", "HOUSE OF REPRESENTATIVES,SENATE", null, null, 0, 0, "2021-07-19T09:44:21.133000-04:00"], [2644597, "bb283776-a866-4bf8-87c7-02de865d100b", "Q2", "TREMONT STRATEGIES GROUP LLC (F/K/A ADS VENTURES)", 90250, "AMAG PHARMACEUTICAL", 2021, "second_quarter", "PHA", "Pharmaceutical issues; access to women's health pharmaceutical products.", "HOUSE OF REPRESENTATIVES,SENATE", 75000, null, 0, 0, "2021-07-19T09:48:28.113000-04:00"], [2644937, "0b9b428d-c9dc-4dbb-8f75-8a90a56b72eb", "Q2", "MOVEON.ORG CIVIC ACTION", 401106098, "MOVEON.ORG CIVIC ACTION", 2021, "second_quarter", "PHA", "HR 3, Elijah E. Cummings Lower Drug Costs Now Act; S 898, Fair Accountability and Innovative Research Drug Pricing Act of 2021", "Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE", null, 20000, 0, 0, "2021-07-19T10:38:44.127000-04:00"], [2645332, "6b016906-7ad7-49d4-89e5-db5352bf3ac9", "Q2", "CHRISTOPHER HEINZ", 318298, "PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION", 2021, "second_quarter", "PHA", "Prescription drug industry issues relating to domestic construction and maintenance employment and all other issues affecting employment in the industry, generally.", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2021-07-19T11:16:08.523000-04:00"], [2645456, "715b36a1-42db-43d4-b137-06f95b134b3f", "Q2", "KOUNTOUPES DENHAM CARR & REID, LLC", 320918, "CVS HEALTH", 2021, "second_quarter", "PHA", "General education about the pharmacy benefit manager/pharmacy and insurance industry.  Issues related to drug pricing.  Issues related to the drug supply chain.  Issues related to the implementation of H.R. 133, Consolidated Appropriations Act for Fiscal Year 2021.  Issues related to the implementation of H.R. 1319, The American Rescue Plan, including provisions related to vaccine distribution.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2021-07-19T11:28:39.737000-04:00"], [2645679, "f0f10825-50d4-441a-af7d-e6763a712f65", "Q2", "LUNGREN LOPINA LLC", 401103314, "AMPAC FINE CHEMICALS", 2021, "second_quarter", "PHA", "Fair treatment for US based pharmaceutical ingredients", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2021-07-19T11:50:34.520000-04:00"], [2645984, "41e6017c-e185-40ed-8662-2794d1367d33", "Q2", "BROWNSTEIN HYATT FARBER SCHRECK, LLP", 7257, "WALGREEN CO.", 2021, "second_quarter", "PHA", "Pharmacist provider status, Pharmacy benefits on military bases, Issues related to COVID-19 relief \nH.R.1319 - American Rescue Plan Act of 2021", "HOUSE OF REPRESENTATIVES,SENATE,State, Dept of (DOS)", 60000, null, 0, 0, "2021-07-19T12:17:40.427000-04:00"], [2646160, "e8fbf3a0-225d-4db5-933b-8a3a9b3588e8", "Q2", "KOUNTOUPES DENHAM CARR & REID, LLC", 320918, "BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY)", 2021, "second_quarter", "PHA", "Issues related to the cost of care and protecting patient access to blood cancer treatment.  Issues related to specialty drug tiers.", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office", 50000, null, 0, 0, "2021-07-19T12:36:20.180000-04:00"], [2646199, "331ea68b-2029-4799-a620-6f4446477a91", "Q2", "THORSEN FRENCH ADVOCACY LLC", 400599826, "HEALTHCARE DISTRIBUTION ALLIANCE", 2021, "second_quarter", "PHA", "Issues related to regulation of prescription opioid medication. \nIssues related to vaccine distribution. \nH.R.133: Consolidated Appropriations Act, 2021.\nH.R.786: Supporting State and Local Leaders Act.\nH.R.768: Block, Report, And Suspend Suspicious Shipments Act of 2021.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2021-07-19T12:40:30.660000-04:00"], [2646207, "133024d4-768c-492c-bed6-675d44e0bef5", "Q2", "FOLEY & LARDNER LLP", 15042, "ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY", 2021, "second_quarter", "PHA", "FDA issues; Issues relating to prescription drug abuse; Issues relating to CDC guidance for prescribing opioids; Issues relating to removal of FDA unapproved products from the market.", "HOUSE OF REPRESENTATIVES,SENATE", 70000, null, 0, 0, "2021-07-19T12:41:32.600000-04:00"], [2646289, "1a7e0d23-9588-469b-a9fb-df615739807a", "Q2", "THORSEN FRENCH ADVOCACY LLC", 400599826, "PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA", 2021, "second_quarter", "PHA", "Issues related to pharmaceutical market value.\nGlobal supply chain.", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2021-07-19T12:49:56.397000-04:00"], [2646418, "4534f03a-238e-4a2a-a057-e56f2ca91f47", "Q2", "CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER", 312496, "CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER", 2021, "second_quarter", "PHA", "340B", "Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office", null, 32870, 0, 0, "2021-07-19T13:03:27.927000-04:00"], [2646749, "e75e60d9-1d19-4db5-b238-c8a266c6db1f", "Q2", "SUMMIT PUBLIC AFFAIRS", 401105467, "VANDA PHARMACEUTICALS INC.", 2021, "second_quarter", "PHA", "Issues affecting the pharmaceutical industry, including the prescription drug approval process, animal testing, and gastroparesis issues.\nImplementation of the American Rescue Plan Act of 2021 (Pub. L. No. 117-7).\n21st Century Cures Act 2.0 (proposed legislation).", "Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2021-07-19T13:45:44.917000-04:00"], [2646792, "c1247a24-8f46-4d4c-9d83-7a946fdab839", "2A", "TARPLIN, DOWNS & YOUNG, LLC", 304736, "ASTRAZENECA", 2021, "second_quarter", "PHA", "Drug coverage & reimbursement\nvaccination\n\nno specific bills, Import Safety, drug development policy, drug shortages, supply chain integrity, Innovation, reimportation, transparency, 340B, pay for delay", "Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 80000, null, 0, 0, "2021-07-19T13:48:53.687000-04:00"], [2646957, "7fcfa42e-7a57-4e0e-bf45-d7c0f7791c80", "2A", "TARPLIN, DOWNS & YOUNG, LLC", 304736, "BIOTECHNOLOGY INDUSTRY ORGANIZATION", 2021, "second_quarter", "PHA", "H.R. 1319, American Rescue Plan of 2021 implementation\n\n\nno specific bills, Drug Safety, Prescription Drug Importation, Import Safety, supply chain integrity, biosimilars, patent settlements, break through therapies, Innovation, transparency\n\nno specific bills, Drug Safety, Prescription Drug Importation, Import Safety, supply chain integrity, biosimilars, PDUFA and associated policies, patent settlements, accelerated approval, break through therapies, compounding, user fee reauthorization, Innovation", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE", 80000, null, 0, 0, "2021-07-19T14:05:28.917000-04:00"], [2647246, "b100644f-f822-42d6-aceb-3ba023d970ba", "Q2", "GOVERNMENT COUNSEL, LLC", 401105070, "HEALTHCARE DISTRIBUTION ALLIANCE", 2021, "second_quarter", "PHA", "H.R. 768-Block, Report, And Suspend Suspicious Shipments Act of 2021; General issues relating to implementation of Public Law 113-54 (DSCSA;Pandemic Vaccine Tracking Improvement Act Discussion Draft.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2021-07-19T14:25:27.810000-04:00"], [2647648, "feb66008-6093-4d35-83ab-1fd59a58e1df", "Q2", "TARPLIN, DOWNS & YOUNG, LLC", 304736, "HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.)", 2021, "second_quarter", "PHA", "Opioid Abuse - General issues related to opioid abuse (implementation of Public Law 115-271)\nIssues related to ARCOS data and suspicious order record requirements and reporting (HR 768) \nImportation of Prescription Drugs (HR 832, HR 2181, S 259, S 920, Public Law 108-173) \nImplementation of Public Law 113-54 (DSCSA)", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 80000, null, 0, 0, "2021-07-19T14:57:05.963000-04:00"], [2647784, "a3f4e0cb-2d1c-45eb-8802-b2ae40aeddd2", "Q2", "ISEMAN & ASSOCIATES LLC", 401103582, "TICHENOR VENTURES, LLC", 2021, "second_quarter", "PHA", "Monitoring biotech legislation; prescription drug prices", "HOUSE OF REPRESENTATIVES,SENATE", 10000, null, 0, 0, "2021-07-19T15:06:36.883000-04:00"], [2648235, "79b788b5-90ab-4b1b-8fb4-4d7efd1cf07d", "Q2", "NATIONAL ASSOCIATION OF SPINE SPECIALISTS", 400395865, "NATIONAL ASSOCIATION OF SPINE SPECIALISTS", 2021, "second_quarter", "PHA", "H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act\nIssue: Requested clarification on certain key provisions reducing patients' access to medically-necessary treatments.", "HOUSE OF REPRESENTATIVES,SENATE,White House Office", null, 60000, 0, 0, "2021-07-19T15:38:21.937000-04:00"], [2648301, "e9aaa50d-96ad-4e23-9280-fad3b45cc608", "Q2", "THERMO FISHER SCIENTIFIC INC.", 323251, "THERMO FISHER SCIENTIFIC INC", 2021, "second_quarter", "PHA", "Worker training program.", "Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Education, Dept of,Environmental Protection Agency (EPA),Executive Office of the President (EOP),Food & Drug Administration (FDA),General Services Administration (GSA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Transportation, Dept of (DOT)", null, 1020000, 0, 0, "2021-07-19T15:42:35.600000-04:00"], [2648684, "c6c07931-e4f6-4c73-84cf-6ec9792a288b", "Q2", "NATIONAL ASSOCIATION OF BENEFITS AND INSURANCE PROFESSIONALS", 26808, "NATIONAL ASSOCIATION OF BENEFITS AND INSURANCE PROFESSIONALS", 2021, "second_quarter", "PHA", "H.R. 3 (Elijah E. Cummings Lower Drug Costs Now Act): This bill establishes several programs and requirements relating to the prices of prescription drugs.\nH.R. 19 (Lower Costs, More Cures Act of 2021): To provide for certain reforms with respect to the Medicare program under title XVIII of the Social Security Act, the Medicaid program under title XIX of such Act, the Food and Drug Administration, and for other purposes.\nH.R. 3775 (State-Based Universal Health Care Act of 2021): To amend title I of the Patient Protection and Affordable Care Act to authorize the establishment of, and provide support for, State-based universal health care systems that provide comprehensive health benefits to State residents, and for other purposes.\nS. 1180 (Choose Medicare Act): Would establish a Medicare Part E that individuals and employers can opt into.\n\nH.R. 1319 (American Rescue Plan Act): To provide for reconciliation pursuant to title II of S. Con. Res. 5.\nS. 1180: Choose Medicare Act: Would establish a Medicare Part E that individuals and employers can opt into.\nH.R. 1868 (Medicare Sequester): Extends a suspension of Medicare sequestration and make other technical changes to Medicare payments and Medicaid eligibility.", "Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Labor, Dept of (DOL),SENATE,Treasury, Dept of,White House Office", null, 330000, 0, 0, "2021-07-19T16:07:00.123000-04:00"], [2648709, "9d88a5c3-b0f8-4aca-a67e-a16e727a34ac", "Q2", "AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS", 3457, "AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS", 2021, "second_quarter", "PHA", "Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its subagencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Contact FDA concerning the practice of White Bagging and Brown Bagging patient medications.", "Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE,White House Office", null, 320000, 0, 0, "2021-07-19T16:09:07.197000-04:00"]], "truncated": false, "filtered_table_rows_count": 287, "expanded_columns": [], "expandable_columns": [[{"column": "filing_uuid", "other_table": "lobbying_filings_raw", "other_column": "filing_uuid"}, "registrant_name"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, filing_uuid, filing_type, registrant_name, registrant_id, client_name, filing_year, filing_period, issue_code, specific_issues, government_entities, income_amount, expense_amount, is_no_activity, is_termination, received_date from lobbying_activities where \"filing_period\" = :p0 and \"filing_year\" = :p1 and \"issue_code\" = :p2 order by filing_year desc limit 101", "params": {"p0": "second_quarter", "p1": "2021", "p2": "PHA"}}, "facet_results": {"issue_code": {"name": "issue_code", "type": "column", "hideable": false, "toggle_url": "/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2021&issue_code=PHA", "results": [{"value": "PHA", "label": "PHA", "count": 287, "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2021", "selected": true}], "truncated": false}, "filing_year": {"name": "filing_year", "type": "column", "hideable": false, "toggle_url": "/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2021&issue_code=PHA", "results": [{"value": 2021, "label": 2021, "count": 287, "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&issue_code=PHA", "selected": true}], "truncated": false}, "filing_period": {"name": "filing_period", "type": "column", "hideable": false, "toggle_url": "/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2021&issue_code=PHA", "results": [{"value": "second_quarter", "label": "second_quarter", "count": 287, "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_year=2021&issue_code=PHA", "selected": true}], "truncated": false}}, "suggested_facets": [{"name": "filing_type", "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2021&issue_code=PHA&_facet=filing_type"}, {"name": "received_date", "type": "date", "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2021&issue_code=PHA&_facet_date=received_date"}], "next": "2021,2648709", "next_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2021&issue_code=PHA&_next=2021%2C2648709&_sort_desc=filing_year", "private": false, "allow_execute_sql": true, "query_ms": 2042.1405090019107, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}